Pemvidutide: Uses, Benefits & Research

What is Pemvidutide?

Pemvidutide is a synthetic 41-amino acid peptide developed by Altimmune that acts as a dual GLP-1 and glucagon receptor agonist. Administered as a once-weekly subcutaneous injection at doses of 1.2 mg to 2.4 mg, it is being investigated primarily for metabolic-associated steatohepatitis (MASH), obesity, and — in a novel expansion — alcohol use disorder and alcohol-associated liver disease.

The FDA granted Fast Track designation for pemvidutide in MASH treatment, reflecting the Phase 2b IMPACT trial’s strong results. As of March 2026, pemvidutide remains investigational with no FDA approval.

Mechanism of Action

Pemvidutide’s dual mechanism targets two complementary metabolic pathways:

GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion, suppresses appetite through central satiety signaling, and delays gastric emptying. This component is shared with approved GLP-1 receptor agonists like semaglutide and liraglutide.

Glucagon receptor activation: Enhances hepatic energy expenditure and lipid oxidation in the liver. For MASH specifically, this pathway is particularly relevant — glucagon signaling promotes liver fat mobilization and metabolism, directly addressing the hepatic steatosis that drives disease progression.

The combination of GLP-1 (appetite/insulin) and glucagon (liver fat/energy expenditure) may explain pemvidutide’s strong MASH resolution signal, where liver-directed effects are critical beyond weight loss alone.

Clinical Evidence

Human Studies

• Phase 2b IMPACT Trial (MASH, PMC12529369): Randomized, double-blind, placebo-controlled trial in adults with MASLD/MASH. At 24 weeks, 59.1% of patients achieved MASH resolution without worsening of fibrosis — meeting the primary endpoint. Significant fibrosis improvement was also demonstrated. 48-week data readout expected Q4 2025.
• Phase 2 MOMENTUM Trial (Obesity, 2024): Randomized, double-blind, placebo-controlled trial in adults with obesity showing meaningful weight loss and acceptable safety through 48 weeks.
• Phase 2 RECLAIM Trial (AUD): Initiated Q3 2025 for alcohol use disorder — an innovative GLP-1 class application.
• Phase 2 RESTORE Trial (ALD): Initiated Q3 2025 for alcohol-associated liver disease.

Preclinical

Preclinical studies confirmed dual GLP-1R and GCGR agonist activity, enhanced weight reduction and metabolic improvement in animal models, and supported hepatic lipid reduction mechanisms.

Drug Interactions & Contraindications

No formal drug interaction studies have been published. Theoretical concerns follow the GLP-1 receptor agonist class: additive hypoglycemia with insulin or sulfonylureas, delayed absorption of co-administered oral medications, and potential alcohol interactions being studied in the AUD/ALD trials.

Contraindicated in patients with hypersensitivity to the compound, personal or family history of medullary thyroid carcinoma, and MEN2 syndrome.

Safety & Side Effects

The Phase 2 safety profile is consistent with the GLP-1 receptor agonist class — nausea, vomiting, diarrhea, decreased appetite, and injection site reactions are the most commonly reported adverse events. No new safety signals were identified in Phase 2 trials. Theoretical concerns based on the dual mechanism include gastroparesis risk, hepatic safety in liver disease populations, and thyroid C-cell tumor risk (GLP-1 class effect).

Honest Bottom Line

Pemvidutide is a promising GLP-1/glucagon dual agonist with a strong Phase 2b signal in MASH — 59.1% resolution without fibrosis worsening is a clinically meaningful result that earned FDA Fast Track designation. The expansion into alcohol use disorder represents a genuinely innovative application of the GLP-1 mechanism class. However, pemvidutide remains in Phase 2b with no FDA approval, and the 48-week IMPACT data will be critical for Phase 3 planning. The competitive landscape includes survodutide, efinopegdutide, and approved GLP-1 monotherapies. For patients with MASH or obesity, pemvidutide is worth monitoring but is not yet accessible outside clinical trials.